Better care at lower prices? Not so fast, reform-reactive hospital mergers

A probing study of hospital pricing released Dec. 15 may cause state policymakers and attorneys general to re-think the urge to OK hospital mergers as a way to make the Affordable Care Act work for them—at least if their aim is to help cut the cost of care for patients in their respective markets.

Yes, multi-hospital healthcare systems tend to spend less on Medicare, but they also take advantage of their competitive edge or monopoly by setting markedly higher prices for private payers, according to the analysis.

The 55-page study report comes from a team of health-policy and economics researchers from Yale, the University of Pennsylvania, Carnegie Mellon University and the London School of Economics and Political Science.

“We find that hospitals located in monopoly markets have prices that are about 15.3 percent higher than hospitals located in markets with four or more providers,” they write. “This result is robust across multiple measures of market structure and is consistent in states where the Health Care Cost Institute data contributors (and/or Blue Cross Blue Shield insurers) have high and low coverage rates.”

The work is posted in full online (PDF).

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.